source
- Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's TepezzaViridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…
- Pharma's reputation among patient groups edges up to 57% but access and pricing concerns lingerPatient groups surveyed by research firm PatientView gave drugmakers a 57% “good” or “excellent” reputation rating, the highest level since 2023. The survey covered more than 2,400 groups in 35 cou…